Cargando…
Testing for HER2 in Breast Cancer: A Continuing Evolution
Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor in breast cancer. HER2 is overexpressed in approximately 15%–20% of invasive breast carcinomas and is associated with earlier recurrence, shortened disease free survival, and poor prognosis. Trastuzumab...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
SAGE-Hindawi Access to Research
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005907/ https://www.ncbi.nlm.nih.gov/pubmed/21188214 http://dx.doi.org/10.4061/2011/903202 |